Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
7
EVAX Quote, Financials, Valuation and Earnings
Last price:
$0.87
Seasonality move
:
-43.46%
Day range:
$0.86 - $0.90
52-week range:
$0.85 - $13.61
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.24x
P/B ratio:
70.93x
Volume:
13.1K
Avg. volume:
77.6K
1-year change:
-87.4%
Market cap:
$5.2M
Revenue:
$73K
EPS (TTM):
-$2.80
Analysts' Opinion
-
Consensus RatingEvaxion Biotech AS has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Evaxion Biotech AS has an estimated upside of 1192.23% from its current price of $0.89.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.89.
Fair Value
-
According to the consensus of 0 analysts, Evaxion Biotech AS has 1192.23% upside to fair value with a price target of -- per share.
EVAX vs. S&P 500
-
Over the past 5 trading days, Evaxion Biotech AS has underperformed the S&P 500 by -9.11% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Evaxion Biotech AS does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Evaxion Biotech AS has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Evaxion Biotech AS reported revenues of $3M.
Earnings Growth
-
Evaxion Biotech AS has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Evaxion Biotech AS reported earnings per share of -$0.40.
Enterprise value:
672.8K
EV / Invested capital:
9.09x
Price / LTM sales:
1.24x
EV / EBIT:
--
EV / Revenue:
0.20x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-69.51%
Net Income Margin (TTM):
-347.86%
Return On Equity:
--
Return On Invested Capital:
-238.97%
Operating Margin:
-57.38%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $3.3M | -- | $3M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$26.5M | -$24.3M | -$15.1M | -$5.8M | -$1.7M | |
| EBITDA | -$23.7M | -$24.7M | -$11.2M | -$5.7M | -$1.6M | |
| Diluted EPS | -$10.80 | -$9.50 | -$2.80 | -$2.10 | -$0.40 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $10.4M | $16.3M | $17.9M | $2.6M | $4.6M | |
| Total Assets | $11.3M | $24.1M | $27.4M | $11.9M | $15.2M | |
| Current Liabilities | $3.4M | $3.9M | -- | -- | -- | |
| Total Liabilities | $3.4M | $7.5M | $13.9M | $14.7M | $15.2M | |
| Total Equity | $7.9M | $16.7M | $13.5M | -$2.7M | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2021-06-30 | 2022-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$18.7M | -$23.8M | -$7.5M | -$5.2M | |
| Cash From Investing | -- | -$1.1M | -$744K | -$495K | -$77K | |
| Cash From Financing | -- | $34.1M | $32M | -$35K | -$300K | |
| Free Cash Flow | -- | -$19.8M | -$24.6M | -$8M | -$5.3M | |
EVAX
Sector
Market Cap
$5.2M
$46.1M
Price % of 52-Week High
6.57%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-87.4%
-30.52%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.95
200-day SMA
Sell
Level
$2.92
Bollinger Bands (100)
Sell
Level
1.67 - 3.19
Chaikin Money Flow
Sell
Level
-110.9M
20-day SMA
Sell
Level
$1.24
Relative Strength Index (RSI14)
Sell
Level
21.91
ADX Line
Sell
Level
8.52
Williams %R
Buy
Level
-93.5673
50-day SMA
Sell
Level
$1.88
MACD (12, 26)
Sell
Level
-0.28
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Neutral
Level
79.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-16.357)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
Stock Forecast FAQ
In the current month, EVAX has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EVAX average analyst price target in the past 3 months is --.
-
Where Will Evaxion Biotech AS Stock Be In 1 Year?
According to analysts, the consensus estimate is that Evaxion Biotech AS share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Evaxion Biotech AS?
Analysts are divided on their view about Evaxion Biotech AS share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Evaxion Biotech AS is a Sell and believe this share price will drop from its current level to --.
-
What Is Evaxion Biotech AS's Price Target?
The price target for Evaxion Biotech AS over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EVAX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Evaxion Biotech AS is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of EVAX?
You can purchase shares of Evaxion Biotech AS via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Evaxion Biotech AS shares.
-
What Is The Evaxion Biotech AS Share Price Today?
Evaxion Biotech AS was last trading at $0.87 per share. This represents the most recent stock quote for Evaxion Biotech AS. Yesterday, Evaxion Biotech AS closed at $0.89 per share.
-
How To Buy Evaxion Biotech AS Stock Online?
In order to purchase Evaxion Biotech AS stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
